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Abstract
Cancer is characterized by aberrant patterns of expression of multiple genes. These major shifts in gene expression are
believed to be due to not only genetic but also epigenetic changes. The epigenetic changes are communicated through
chemical modifications, including histone modifications. However, it is unclear whether the binding of histone-modifying
proteins to genomic regions and the placing of histone modifications efficiently discriminates corresponding genes from
the rest of the genes in the human genome. We performed gene expression analysis of histone demethylases (HDMs) and
histone methyltransferases (HMTs), their target genes and genes with relevant histone modifications in normal and tumor
tissues. Surprisingly, this analysis revealed the existence of correlations in the expression levels of different HDMs and HMTs.
The observed HDM/HMT gene expression signature was specific to particular normal and cancer cell types and highly
correlated with target gene expression and the expression of genes with histone modifications. Notably, we observed that
trimethylation at lysine 4 and lysine 27 separated preferentially expressed and underexpressed genes, which was strikingly
different in cancer cells compared to normal cells. We conclude that changes in coordinated regulation of enzymes
executing histone modifications may underlie global epigenetic changes occurring in cancer.
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Introduction
The genome of any multicellular organism contains thousands of
genes; however, only a relatively small proportion of these genes are
expressed in a particular cell type. Part of the critical functional
characteristics between active and repressed states of gene
expression relates to proteins that bind to and modify histone lysine
residues. Histone lysine methylation occurs predominantly within
the amino-terminal tails of histones H3 and H4, in a mono- (me1),
di- (me2) or trimethylation (me3) state, and is associated with a
distinct transcriptional outcome. These diverse methylated residues
areboundbymultiple‘‘reader’’proteins,whichinturninteract with
transcriptional activators or repressors. H3K4me2/3, H3K36me1/
3, H3K79me1/2 and H4K20me1 are associated with transcrip-
tional activation, while H3K9me2/3, H3K27me2/3, H3K79me3
and H4K20me3 are associated with transcriptional repression.
With the recent discovery of histone demethylases, modification of
histone lysine residues is now viewed as a more dynamic process
than previously thought. Multiple studies have shown that histone-
modifying enzymes target specific genes, some of which participate
in specific biological processes and pathways. It is still under debate
whether targets of a histone-modifying enzyme achieve regulation
as a single module, allowing coordinated change in expression in
various biological processes, including diseased conditions, or
represent a mix of differentially expressed genes.
Histone demethylases are represented by a few flavin-dependent
amine oxidases and a-ketoglutarate-Fe(II)-dependent dioxygenases
that are included in a large superfamily of the JmjC domain
proteins (Table S1). Histone methylation is also accomplished by
multiple enzymes, and in most cases involves a catalytic SET
domain (Table S1) related to yeast Set1 and Drosophila Trithorax.
The same modification can be executed by several enzymes, which
in most cases are members of the same protein family, suggesting
their functional specialization through differential expression
patterns. Histone demethylases removing the methyl groups from
histone H3K4 are encoded by two autosomal genes, KDM5A/
JARID1A/RBP2 and KDM5B/JARID1B/PLU1, and two genes
located on the sex chromosomes, KDM5C and KDM5D, and
increasing evidence supports individual and nonredundant roles
within this family [1]. Therefore, it is conceivable that the overall
epigenetic landscape is dependent on the spatial and temporal
distribution of corresponding HDM and HMT enzymes. KDM5A
is directly bound to H3K4me3 in vivo [2]. Despite the repressive
demethylase activity associated with KDM5A function in
demethylation at histone H3K4, it plays a role in both
transcriptional repression and activation [3]. KDM5A contains
not only an enzymatic domain but also a highly specific H3K4me3
reader domain [4], which without doubt could affect other
modifications nearby either cooperatively or antagonistically.
Consistent with these observations, our ChIP-on-chip analysis
showed that KDM5A binding to genomic loci highly correlates
with transcriptionally active promoters containing H3K4me3 and
other modifications associated with transcriptional activation, such
as H3K36me3, H3K79me2 and acetylation at H3K9 and K14,
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identified for families of enzymes like KDM5, it will be of
particular interest to understand their contribution to histone
H3K4 methylation in promoter- and cell type-dependent manner.
Genomic analyses in Drosophila and mammals showed that
Trithorax group (TrxG) genes antagonize regulation by Polycomb
group (PcG) genes to create a repertoire of alternative states of
gene expression. Accumulating evidence has shown that recruit-
ment of HMTs or HDMs of opposing activity to the same genomic
regions underlies important developmental decisions. In particu-
lar, the HMTs MLL1 and EZH2 are components of the Trithorax
and Polycomb complexes, respectively, that play an important role
in the regulation of developmental genes in both Drosophila and
vertebrates. Based on the enhancement of phenotype of trxG
mutations and suppression of phenotype of PcG mutations, the
KDM5A ortolog in Drosophila, gene lid belongs to the trxG group
gene [6]. The effects of mutations in the PcG and TrxG genes in
Drosophila led to the paradigmatic view of homeotic (HOX) gene
regulation. In vertebrates, HOX genes are also sensitive to loss of
the H3K4-specific HMT MLL1 or HDM KDM5A, and H3K27-
specific HMT EZH2 [4,7,8,9,10]. As in Drosophila, deletion of the
MLL1 SET domain in mice results in a homeotic phenotype [11].
Importantly, rearrangements of the MLL1 gene in humans are
involved in the pathogenesis of a variety of aggressive human
leukemias. The disregulation of HOX genes by MLL1 fusion
proteins appears to play a central role in this transformation [9].
Following elucidation of the role of MLL translocations in the
pathogenesis of leukemia came the discovery of a KDM5A
leukemia oncogenic lesion, resulting in the deregulation of HOX
and other lineage-specific genes [4]. Considering the requirement
for the proper level of expression for each of these enzymes
involved in HOX gene regulation, it is conceivable that each state
is the result of a combined activity of histone modifying enzymes.
A recent study suggested that this explains dynamics of each state,
when switching to a different state is dependent on the relative
levels of PcG, TrxG and activators in cis-regions of the locus [12].
In particular, differentiation of stem cells involves the resolution of
the poised state of ‘‘pluripotency genes’’ and lineage-specific genes
through a change in the balance of PcG and TrxG complexes.
These genes were found to be enriched for bivalent H3K4me3 and
H3K27me3 marks. In contrast, cells can regain stem-cell
characteristics through reactivation of pluripotency genes and
repression of the lineage-specific program, which was associated
with the resolution of bivalent mark into the corresponding
univalent mark. The ability of cells to maintain the poised,
repressed or fully active states of these genes [12] is critical for
progression to a cancerous state. It has been hypothesized that
underlying these events is a change in the TrxG/PcG balance in
favor of a particular complex [13].
It is somewhat surprising that, despite the large amount of newly
generated gene-expression data in normal or tumor tissues, there
were no expression studies of targets of histone modifying enzymes
at the global level. Using representative, internally consistent
expression datasets from a variety of normal and tumor tissues and
from cell lines, we have identified cell types and tumors where the
genes encoding HDMs and HMTs are prominently expressed and
underexpressed. Previous studies have shown dependence of
expression of particular HDM/HMT target genes on the level
of a HDM or HMT. Here we analyzed large sets of epigenetically
regulated genes, including a set of direct targets of KDM5A, a set
of direct targets of EZH2, and sets of H3K4 and H3K27
trimethylated genes. Strikingly, our analysis revealed that the
whole set of genes can highly correlate in expression with the level
of gene expression of the corresponding enzyme. Consistent with
opposing activities of TrxG and PcG proteins, this analysis
revealed anti-correlation in the expression of KDM5A and EZH2
targets, and of genes characterized by relevant histone modifica-
tions. This study enabled identification of sets of co-regulated
HDMs and HMTs, comprising a HDM/HMT gene expression
signature. The correlations that we observed in normal tissues
were different from correlations identified in cancer cells.
Considering multiple alterations in HDM and HMT genes in
cancer cells, it seems that using this approach could yield new
functional connections between histone modifying enzymes, which
might be helpful in designing a combination cancer therapy.
Results
Correlations in expression of HDMs, HMTs, their targets
and genes with histone H3K4 and H3K27 methylation
The most widely studied marks of active and repressed
chromatin are on histone H3 methylated at K4 and at K27,
respectively. KDM5A significantly overlaps with the H3K4me3
marks at the regions around the transcription start sites, and
EZH2 binds throughout H3K27me3 regions [14]. We previously
showed that consistent with the presence of H3K4me3 mark at the
genes occupied by KDM5A in U937 cells, these regions were
highly transcriptionally active in U937 cells [5]. We also described,
using z-score analysis, preferential expression of this set of
KDM5A targets in human tissues [5]. This suggested that
KDM5A target genes form a module characterized by higher
expression and presence of H3K4me3. While it is generally
assumed that both features are dependent on presence of enzymes
involved in H3K4 methylation, the correlation between the level
of expression of this module and enzyme in the same cells has not
been demonstrated.
Given the differential expression of KDM5A module in
particular tissues, we examined if KDM5A is also differentially
expressed in the same tissues. Indeed, analysis of KDM5A
normalized expression data from the compendium of human
tissue samples in GeneAtlas (BioGPS database) showed that
KDM5A is highly expressed in cells derived from bone marrow and
peripheral blood, where its target genes are preferentially
expressed (z-score .1.96) (Figure 1A and B, Table S2 and Table
S3). Using Pearson’s correlation coefficient (PCC) to describe the
correlation in expression of KDM5A module with the level of
KDM5A, we found that the correlation was very significant across
all tissues (PCC=0.65 in Figure 1C and Table S4).
One interesting question is to compare expression of targets of a
HDM/HMT with general expression of genes with the relevant
histone modification. Given the direct binding of KDM5A to
H3K4me3 [2], we analyzed expression of genes displaying
H3K4me3 and compared it to the expression of KDM5A targets.
Previously we showed that if we take in our analysis diffuse
histiocytic lymphoma U937 cells or U937 cells differentiated in
monocytes and macrophages, despite different sets of KDM5A
targets, the analysis shows their preferential expression in the same
set of tissues [5]. Therefore, in subsequent analyses we deliberately
used gene targets obtained from different cell lines. We continued
using KDM5A dataset from U937 cells but used H3K4me3
dataset from breast adenocarcinoma MCF7 cells [15]. Using these
datasets, we found that tissues with overexpression of KDM5A and
KDM5A target genes also display preferential expression of genes
displaying H3K4me3. Comparison across the GeneAtlas tissues
showed that the genes with H3K4me3 were preferentially
expressed in the same tissues where KDM5A target genes were
overexpressed (PCC=0.74), suggesting that the overexpression of
KDM5A target genes is due to H3K4 methylation.
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expression values of H3K4-specific HDM KDM5A, and H3K4-specific HMTs in 73 different normal human tissues (BioGPS database) are delineated in a
color-coded heatmap, where red indicates higher expression of a gene and green indicates lower expression. The expression values and sample
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the HDM KDM5A, we asked whether we could identify an H3K4
HMT whose level correlated with KDM5A expression level, and
may account for higher expression of H3K4me3 module in
GeneAtlas. We observed relatively uniform expression for MLL2,
MLL3, SET1B and SET7 across different tissue samples (Figure 1A
and Table S2). In contrast, MLL1, SET1A, PRDM9 and SMYD3
demonstrated highly tissue-specific patterns of expression. SMYD3
displayed prominent expression in the central nervous system.
There was higher expression of MLL1 in hematopoietic cells,
especially in CD4
+ and CD8
+ T-cells, displaying preferential
expression of H3K4me3 module. Consistent with these observa-
tions, mouse CD4
+CD8
+ T-cells are known to express the MLL1
gene [16] and H3K4 methylation correlates highly with gene
activation in CD4
+ T cells [17]. Using PCC to describe the
correlation in expression level in different gene pairs, we found
that KDM5A and MLL1 displayed high correlation of expression of
(PCC=0.58 in Figure 1D and Table S5). As well as in blood cells,
MLL1 and KDM5A show high expression levels in the pineal gland,
and this correlated with the higher expression of H3K4me3
module. The pineal gland establishes a circadian rhythm for the
circulating hormone melatonin. Several histone modifications
associated with activated transcription have been shown to
oscillate in the pineal gland [18]. MLL1 and KDM5A may
contribute to differential transcription in the pineal gland, which
may be as high as 100-fold, through oscillation of H3K4me3.
These data suggest that multiple H3K4 HMTs exhibit highly
tissue-specific patterns of expression. There is a consistent pattern
of tissue specificity in the expression of MLL1 and KDM5A, two
histone-modifying enzymes involved in leukemia. Their levels
might be adjusting to fulfill requirements in H3K4-mediated
processes.
The above result was consistent with a significant overlap
between KDM5A targets and H3K4me3 regions in multiple cell
lines [14]. To examine if the same true for targets of other histone
modifying enzymes, we analyzed expression of genes with
H3K27me3 from the same study in MCF7 cells and of EZH2
target genes determined in ES cells [19]. Again, we found high
correlation in the level of expression of both modules (Figure 1B
and 1C). Unexpectingly, in the same tissues where KDM5A
targets were preferentially expressed, the EZH2 targets were
significantly underexpressed (PCC=-0.68 in Figure 1C and Table
S4), which highly correlated with underexpression of genes
displaying H3K27 methylation (PCC=20.82). Target genes
determined for EZH2 were underexpressed in cells derived from
bone marrow and peripheral blood (z-score ,21.96) (Figure 1B).
Strikingly, in differentiated tissues such as brain the gene
expression states were the opposite, with overexpression of the
EZH2 module and underexpression of the KDM5A module.
However, the anti-correlative behavior between the level of
expression of both modules remained in all tissues. These data
indicate on the existence of an intimate crosstalk in establishing
expression levels of KDM5A module and EZH2 module. This
represents an important observation suggesting that epigenetic
landscape can be described as a simple combination of modules
dependent on HDM/HMT expression.
HDM and HMT tissue-specific expression profiles
Within JmjC genes, 12 gene families can be defined on the basis
of phylogenetic information and overall domain structure [20].
Many of these families have experienced birth-and-death evolu-
tion, including duplication in one lineage and loss in another
lineage. The KDM5 subfamily, where different gene members have
highly specialized functions, emerged from gene duplication events
after the divergence of vertebrates from insects. Indeed, different
KDM5 family genes display tissue-specific expression, reflected not
only in sex-specific expression but also in autosomal expression
(Figure 2A). In addition, some tissues may depend less on histone
demethylases than other tissues, and methylation may instead be
removed by other mechanisms. To address this, we asked whether
there were tissues expressing HMTs with an undetectable or low
level of HDMs. We found that the prostate was relatively deficient
in HDMs while showing relative higher expression of HMTs
(Figure 2A). An increase in HMT activity could potentially lead to
histone hypermethylation in prostate carcinoma patients. In
contrast, preferential expression of HDMs was observed in the
hematopoietic system, while HMTs were highly expressed in the
liver. Surprisingly, the brain was relatively deficient in both HDMs
and HMTs. To find if the HDM/HMT expression pattern stays the
same during neeoplastic transformation, as the first step, we
performed similar analysis from cancer cell lines from GSK
dataset. The expression pattern was drastically different in cancer
cell lines compared with cells from normal tissue (Figure 2A and
2B). While HDMs were generally underexpressed in the prostate
and brain tissues of healthy individuals (Figure 2A), particular
HDMs were found to be overexpressed in prostate and brain
cancer-derived cells (Figure 2B).
Cancer type-specific gene expression changes in HDMs/
HMTs and their targets
Based on the analysis above, we hypothesized that coordinated
regulation underlying functional interactions among cooperating
and opposing HDM and HMT activities is critical for tumors as
well as for normal tissue, but that in tumors we would detect
distinct correlations in gene expression. To test this hypothesis, we
used the GSK dataset, the largest collection of gene expression
data available for cancer cell lines. This set of 264 samples mostly
includes hematopoietic and lung cancer-derived cell lines, and
varying numbers of cell lines from 16 other tissues (Table S6). We
performed unsupervised hierarchical clustering of samples in order
to identify an HDM gene expression signature in cancer. This
analysis revealed three large clusters (Figure 3A). Surprisingly,
when the cell lines were arranged according to HMT expression, it
showed a similar grouping (data not shown), suggesting that
expression of HDMs and HMTs is interdependent. We found that
annotation are presented in Table S2. Several genes, including KDM5A and MLL1, display higher expression in a small set of cell types. (B) Z-score
values for preferential expression and underexpression of target genes of KDM5A (U937 cells), EZH2 (ES cells) and genes displaying H3K4me3 or
H3K27me3 (MCF-7 cells). Z-score values are delineated in a different colored heatmap, where red signifies overexpression of targets and blue signifies
underexpression of targets; grey indicates no significant difference from expected value. (C) Pearson correlation coefficient (PCC) of the expression
level of KDM5A, EZH2 and of gene modules in (B). Expression of KDM5A module and of H3K4me3 module correlates with expression of KDM5A gene.
Strikingly, expression of both modules displays negative correlation with the expression of EZH2 module and H3K27me3 module. (D) PCC of the
expression profile of any pair of genes in (A). A high correlation is displayed between KDM5A and the MLL1 gene expression, which may account for
the general correlation of KDM5A and its targets in (C). PCC values are depicted in a color-coded heatmap using a standard 1 bases scale, where
magenta (+1) shows higher positive correlation and green (21) shows higher anti-correlation. The PCC values for (C) and (D) are provided in Tables S4
and S5.
doi:10.1371/journal.pone.0024023.g001
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lung cancer cell lines were found in all three major clusters but
were restricted to subclusters. The main cluster 1 (in the red boxed
area) showed relatively high expression and comprised hemato-
poietic cell lines. Cluster 2 (in the blue boxed area) was formed by
skin, pancreas and bone cell lines, which showed relatively low
expression. Cluster 3 (in the yellow boxed area) showed
intermediate expression, with breast, colon and central nervous
system cancer cell lines forming this group.
Several lines of evidence support the accuracy of the revealed
HDM/HMT gene expression signatures. Consistent with deregu-
lation of KDM5A in leukemia [4], this gene was prevalently
expressed in cluster 1, and the KDM5A overexpression seen in lung
cancer cell lines may be due to their CD133-positive character
[21]. Expression of the KDM5A homolog PLU1/KDM5B was, in
contrast, very different from KDM5A expression. KDM5B was
absent from cluster 1 and was very highly expressed in breast
carcinoma cell lines in cluster 3. Previous studies showed KDM5B
overexpression in advanced breast carcinoma and breast cancer
cell lines [22]. Consistent with upregulation of EZH2 in aggressive
cancers [23], the clustering revealed high expression of EZH2 in
cluster 1, which contained samples from highly aggressive blood
and lung cancers.
Because HDM and HMT displayed cancer-specific gene
expression signature, we asked whether correlations in their target
gene expression or in the expression of genes marked with histone
methylation are lost in cancer samples. We acquired expression
data for KDM5A targets and EZH2 targets from the GSK dataset
and applied z-score analysis to study the significance of their
combined up- or downregulation in different cancer cell lines
samples. We found that similar to normal cells, EZH2 targets are
strongly biased towards similar expression with the H3K27me3
module (PCC=0.86), while KDM5A module displayed anti-
correlative behavior to the expression of EZH2 module
(PCC=20.67) and H3K27me3 module (PCC=20.73)
(Figure 3B). Samples with the highest z-score values for KDM5A
module and with the lowest z-score values for EZH2 module were
found in leukemia samples of cluster 1 (Figure 3A and Table S7),
which was consistent with high expression of these modules in
normal blood cell types (Figure 1B). However, in contrast to
normal tissues, there was no tendency for the H3K4me3 module
to be overexpressed in the same cancer samples as the KDM5A
module (PCC=0.07) (Figure 3B, 3C and Table S8). Even more
striking differences were displayed in cluster 2, where most of
HDMs and HMTs were expressed lower. In cluster 2, there were
no significant correlations in expression of any of the four modules
(Figure 3C). Therefore, cancer-specific HDM/HMT gene expres-
sion signature is likely to dictate global changes in histone
methylation affecting target gene expression.
As the GSK samples from the same tumor types clustered
together on the basis of either HDMs or HMTs gene expression, we
asked whether we could reveal any cases of HDM and/or HMT
co-regulation in human cancer. We computed pair-wise associa-
tions among HDMs and HMTs (Table S9), allowing the
identification and visualization of ‘‘enrichment’’ of linked pairs
(Figure 4). We have shown a high correlation between KDM5A
and the MLL1 gene expression, which may account for the general
correlation in expression of KDM5A and its targets (Figure 1).
However, in cancer cells we were unable to detect correlation
between KDM5A and MLL1 expression, even when only
hematopoietic cell lines were considered (PCC=20.03). The
highest PCC values, including the anti-correlation between
Figure 2. Expression of HDMs and HMTs in normal human tissues and human cancer cell lines. (A) Expression of HDMs and HMTsi n
normal human tissues. Gene-normalized expression values (log2) of 26 HDMs and 11 HMTs are presented for eleven tissues (BioGPS database). (B)
Expression of HDMs and HMTs in cancer cell lines. Gene-normalized (log2) expression values were generated for eleven cell lines from GSK dataset.
Expression level for each gene was described in terms of preferential expression and underexpression, which showed relative higher expression of
multiple HDM and HMT genes in cancer cells compared to normal cells.
doi:10.1371/journal.pone.0024023.g002
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ASH1 (PCC=0.82) and KDM2A–MLL1 (PCC=0.74) pairs, were
revealed in colon cancer cell lines. We found a negative correlation
of EZH2 and MLL1 expression (PCC=20.56) in colon cancer
and positive correlation of EZH2 and KDM1A expression
(PCC=0.65) in lung cancer, suggesting cooperation between
H3K27 methylation and H3K4 demethylation. In many cases, the
revealed associations were clustered by protein families. For
example, expression of PKDM10A, -B and -C displayed a lung
cancer-specific correlation between each other and with other
HDMs and HMTs. Therefore, the new HDM/HMT gene
expression signature may explain the lack of correlation between
the KDM5A module and H3K4 module in cancer (Figure 3B)
compared to normal tissue (Figure 1C). The coordinately
regulated HMTs and HDMs may provide functionality in highly
specific, yet-to-be-identified, biological processes. When combined
with the power of unsupervised hierarchical clustering, PCC
analysis may reveal many other correlating pairs.
Expression of HDMs and HMTs in primary human tumors
After this initial assessment of expression patterns in various
malignancies using cancer cell line data, we next surveyed
transcript levels in hundreds of cancer tissue samples. For these
purposes, we used RT-qPCR analysis, which is a better method
for quantitation of gene expression than microarray studies. While
KDM5A and KDM5B are a highly homologous pair of genes, their
expression patterns in different cell lines varied (Figure 3A). qPCR
analysis for KDM5A and KDM5B levels on a cDNA array
containing 337 samples across 17 tissue types showed that the
KDM5A level was high in the testis and low in lymphoid
malignancies (Figure 5A, Figure S1 and Table S10). In contrast,
the KDM5B level was high in breast tissue, adrenal glands and
cervix (Figure 5A). Consistent with KDM5B overexpression in
malignant breast tumors [22], a highly increase in KDM5B level
was observed in cDNA samples from primary ductal breast
adenocarcinomas (Table S10). KDM5B expression also correlated
with lung tumor stages, increasing in stages IIB, IIIA and IV. In
Figure 1C, we showed that expression of the KDM5A module is
predictive of a level of KDM5A expression, which is lost in cancer
(Figure 3B). While this result is based on calculating median
expression value for all genes in KDM5A module, it is unclear
whether some genes within the module still correlate with KDM5A
gene. Yet, due to the importance of KDM5A in human cancer, it
is critical to identify a gene that could be used as a readout of
KDM5A activity. BRD8 has been identified as a direct target of
KDM5A, positively regulated by KDM5A [3]. In the majority of
samples on the cancer tissue array, we found upregulation of
BRD8 when KDM5A was upregulated and downregulation when
KDM5A was downregulated (Figure 5B and Figure S2). However,
this was not the case for many other genes, KDM5A targets, that
we tested (data not shown). Therefore, BRD8 expression mirrors
KDM5A expression, thus validating it as a marker for KDM5A
level and activity.
Discussion
Analysis of gene expression in different human tissues and cell
lines enabled us to recognize epigenetically regulated genes as
single modules that are dependent on the level of expression of
histone-modifying enzymes (Figure 6). Much of the work done so
has focused on how the binding of these enzymes correlates with
the expression of their target loci. In this study, we conducted
global analysis of the expression level of the enzymes, their targets
and other epigenetically regulated genes. The HDM/HMT gene
expression signatures that we identified are likely to be functionally
significant because of the observed correlation with HDM/HMT
target gene expression as well as with the expression of genes
displaying relevant histone marks. Specifically, there is a strong
bias for both a KDM5A module and a H3K4me3 module to be
preferentially expressed in tissues where KDM5A gene is
overexpressed. The difference in preferential expression of the
H3K4me3 module in leukemia cells compared to normal blood
cells suggests that this gene set may be deficient in methylation due
to a distinct HDM/HMT gene expression signature, which
includes a lack of correlation between KDM5A and MLL1
expression. Furthermore, the KDM5A module displays strong
anti-correlative behavior with an EZH2 module. The overall
conclusion from this study is that the epigenome can be reduced to
a combination of single gene modules, whose expression is a
readout of HDM/HMT gene expression signatures.
Despite of remarkable progress in cancer research, one of the
long-standing questions in the field is correlation between
chromatin modifications and disease. While several studies have
shown associations between a chromatin modifying enzyme, its
representative target genes and patient outcome [24], there have
been no studies linking multiple enzymes. However, sufficient
evidence suggests that cis-interactions are common in chromatin-
mediated transcriptional regulation. H3S10 phosphorylation
enhances H3K4 methylation and H3K14 acetylation, and inhibits
methylation at H3K9, thus facilitating chromatin decondensation
[25]. Analysis of PcG and TrxG interactions and identification of
bivalent marks encouraged the notion that there is a crosstalk
between placing H3K4 methylation and H3K27 methylation at
the same gene. The global analysis conducted here revealed a
strong correlation in expression of genes displaying H3K4
methylation and genes displaying H3K27 methylation, suggesting
that histone modifying activities are coordinated not only in cis-
but also in trans- configuration. While our study does not offer
precise mechanistic concepts to explain this coordination, we show
that it depends on HDM/HMT gene expression signature, which
can be subsequently tested using genetic approaches. We suggest
that the HDM/HMT gene expression signatures result in
maintaining transcriptional equilibriums at H3K4 and H3K27
methylated genes pertinent to a particular fate or to a diseased
condition (Figure 6). Consistent with the paradigm proposed by
Peter Nowell that neoplasia arises from cells with a growth
advantage due to acquired genetic or epigenetic changes [26], a
fundamental feature of cells populating the tumor may be a
Figure 3. Clustering of cancer cell lines based on HDM and HMT gene expression, or on the expression of their targets. (A)
Unsupervised hierarchical clustering of 264 different cancer cell lines of 18 tissue types (GSK database) for the expression of HDMs (left panel) shows
three major clusters. Log2 normalized gene expression is represented by a color-coded heatmap. Red indicates relative higher expression and green
indicates relative lower expression from the gene’s mean of all cell lines. Columns represent genes and rows represent samples. The normalized
expression of different HMTs is presented in the right panel. The legend and scale are as in Figure 2. (B) PCC of the expression level of KDM5A, EZH2
and of gene modules in (C) in cluster 1. PCC values are depicted as in Figure 1. (C) Enrichment analysis, using z-score statistics, of the expression level
of displayed gene modules as in Figure 1(B). The complete list of z-score values for each sample and gene are provided in Table S7. In this dataset, the
samples from the same tumor type clustered together on the basis of either HDMs, HMTs or their target gene expression.
doi:10.1371/journal.pone.0024023.g003
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metastable state. Very little is known what causes the change in
activity of HDM/HMT. Gain of function mutation of EZH2 and
deletion of a microRNA, a negative regulator of EZH2 expression,
have been linked to lymphomas and prostate cancer [27,28].
While change in expression of single histone modifying enzymes
has been linked to cancer, this study represents to our knowledge
the first comprehensive analysis in cancer cell lines. Grouping
cancer samples based on HDM/HMT gene expression signature, it
should be possible to define new combinations of HDMs and
HMTs that have not been considered yet to act directly in
regulating gene modules associated with specific cancers and to
develop novel markers to cancer subtypes.
Association of clinical predictions with genome chromatin
structure was first appreciated in 2005, when Seligson and
colleagues demonstrated that global levels of H3K4me2 and
H3K4me3 are predictors of prostate carcinoma recurrence in
patients with low-grade tumors [29]. We noticed multiple cases
when the difference in expression shown in our heat map
correlated with previously reported data on deregulation of the
gene. Strikingly, MLL1, a frequent leukemia translocation partner,
displays an expression pattern similar to KDM5A, whose
translocation was also shown to be involved in leukemia [4].
Consistent with overexpression of a H3K36me2-specific demethy-
lase KDM2B in T-cell and B-cell acute lymphoblastic leukemia
and in acute myeloid leukemia [30], we found its overexpression in
almost all hematopoietic cell lines. This increase may have
functional significance, as ectopic expression of KDM2B is
sufficient to transform hematopoietic progenitors while its
depletion impairs HOXA9/MEIS1-induced leukemic transforma-
tion [31]. While our observation that cancer cells displayed
changes in the level of multiple histone-modifying enzymes rather
than changes in a particular enzyme seems frustrating at first sight,
the observed highly significant correlations in the levels of different
enzymes gives a promise that targeting one enzyme will be
sufficient to change cancer cell properties. For example, it was
shown that depletion of EZH2 by RNAi in prostate cancer cells
diminished their tumorigenic and metastatic potential in vitro and
in an orthotopic model in nude mice [32]. Strikingly, we found
clusters of lung cancer samples that are more similar in HDM/
HMT gene expression signature to hematopoietic malignancies
(cluster 1 in Figure 3A) than to other clusters of lung cancer
samples, which are more similar to colon and breast cancer
samples (cluster 3 in Figure 3A). Because the HDM/HMT gene
expression signature is similar in some cell types, there is a
potential to use in these cells cancer therapeutics against the same
target. It may be also possible to improve disease prediction
algorithms as an Oncomine Molecular Concept Map (MCM)
study showed that H3K27-methylated genes are downregulated in
lung cancers and the lung gene expression signature was able to
successfully predict the clinical outcome of prostate patients [33].
In contrast to genetic lesions, epigenetic alterations are
potentially reversible, thus holding promise for therapeutic
intervention. ‘‘Erasing’’ this state through inhibitors targeting
DNA methyltransferases and histone deacetylases (HDACs) has
been a widely used treatment for certain hematopoietic cancers
and is being tested in clinical trials for other types of cancer.
KDM5A is increased in drug-resistant cancer cell populations and
Figure 4. Correlation between HDM and HMT gene expression.
The PCC values of any gene pair’s expression profile in hematopoietic,
lung and colon cell lines are depicted in a color-coded heatmap. The
legend and scale are as in Figure 1.
doi:10.1371/journal.pone.0024023.g004
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HDAC inhibitors TSA and SAHA [21]. The involvement of
KDM5A in transcriptional activation may be similar to the active
role played by HDACs at the transcribed regions [34]. Thus, a
combination of HDAC inhibitors and KDM5A inhibitors may be
preferable for treatment of cancer cells with KDM5A overexpres-
sion. The homeotic gene BRD8, which reflects KDM5A activity,
would be useful for testing the effects of KDM5A inhibitors. It is
unclear if other KDM5 family members can be found at active
genes. The KDM5B enables to catalyze demethylation of the same
mark as KDM5A, however, it appears to have different expression
pattern and therefore serve specific requirements in particular
tissues.
While our results are consistent with previous findings on up-
and downregulation of single enzymes, they represent an initial
step to decipher enzyme combinations that can be co-regulated in
cancer. Our data suggest that, in the absence of appropriate
inhibitors to a causative HMT or HDM, pharmacological
targeting of co-regulated HDM/HMT in the same gene expression
signature could be applied to selectively target tumor cells.
Interestingly, we used ChIP-on-chip, ChIPseq and gene expression
data from non-matching cell types and still revealed correlations.
This unexpected result suggests that it wouldn’t be too challenging
a task to conduct a gene expression analysis of the cancer
epigenome since genome-wide data from different studies can be
used. However, we anticipate that the outcome of correlation
analyses will depend on whether the samples are from a more
differentiated tissue or have stem cell properties. Because the
likelihood of detecting a gene expression signature increases with
the number of samples, creating profiles for a particular tumor
type using large datasets will achieve more precision.
Materials and Methods
Normalized mRNA expression data (Affymetrix Human
U133A/GNF1H GeneAtlas microarray chip) [35] from 73 normal
human tissues were downloaded from the BioGPS database [36].
Raw mRNA microarray expression data from various cancer cell
lines (the GSK cancer cell line genomic profiling performed on
Affymetrix GeneChipH U133 Plus 2.0 array) were downloaded
from the National Cancer Institute’s caBIG/caArray databases
(https://cabig.nci.nih.gov/). Three replicates were available for
each cell line. The mean expression was taken and intensity values
were transformed to log2 values. When more than one probe was
present for the same gene, the mean value was determined.
However, in some cases, probes that did not have a good
correlation of expression with respect to other probes of the same
gene, or probes that did not express across any of the samples,
were not included. Log2-converted mean absolute expression
values were represented in a color-coded heatmap (Figure 1) using
the program Matrix2Png (version 1.2, May 2010) [37]. For the
GeneAtlas and GSK data in Figure 2 and 3, expression in each
sample is presented in comparison with the mean value. In
particular, normalized gene expression values were generated by
subtraction of the gene’s mean value followed by division by the
Figure 5. Expression levels of KDM5A, KDM5B and a KDM5A
target gene in human tumors. (A) KDM5A and KDM5B display highly
tissue-specific expression patterns. The figure shows a heatmap of
quantitative real-time PCR experiments in a panel of human tumor
samples. Samples were arranged according to tumor grade, when
information was available. Expression was normalized to the reference
gene B2M and presented relative to the mean DCt of each gene.
Heatmaps were produced using Gitools. The scale ranges from the
minimum value of 0 (green), indicating low relative expression, to the
mid-value of 1 (black) indicating an average level of expression, to the
maximum value of 10 (red) indicating high relative expression. Columns
represent different patient samples. (B) Expression of the KDM5A target
gene BRD8 provides a readout of KDM5A transcript level. Sample
annotation and expression values are presented in Table S9.
doi:10.1371/journal.pone.0024023.g005
Co-Regulation of Histone-Modifying Enzymes
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e24023standard deviation, and were delineated in a color-coded heatmap
using the program Genesis [38]. Unsupervised hierarchical
clustering of samples was performed using the Manhattan
distance. The detailed probe level log2 expression data used in
this study are presented in Table S2. Detailed normalized gene
expression clustered data for cancer cell lines are presented in
Table S6.
Target genes of KDM5A in U937 cell line (0 hr) were obtained
from our previous study [5]. EZH2 targets in human ES cells were
collected from the study by Ku and colleagues [19] and the
genomic locations of enriched histone-binding sites (H3K4me3
and H3K27me3) were obtained from the study by Joseph and
colleagues (GSE23701) [15]. Enriched peaks were annotated to
the closest EnsEMBL gene transcription start site (version 54) [39]
using the Bioconductor package ChIPpeakAnno [40]. Based on
the ‘‘gene-normalized’’ expression of these targets in GeneAtlas
normal cell data and GSK cancer cell line data, we carried out z-
score median enrichment analysis using Gitools (www.gitools.org
[41]), which compares the median expression value of the genes in
each module (KDM5A and EZH2) with a distribution of random
modules of the same size drawn from the expression values for the
sample. The result is a z-score, which is a measure of the difference
between the observed median expression value compared with the
expected value. Positive and negative z-scores indicate significantly
higher or lower expression level of genes in the module under this
condition, respectively.
Pearson’s correlation coefficient (PCC) of HDM and HMT
expression profiles in normal tissues and cancer cell lines was
analyzed using Gitools.
We used the TissueScan Cancer Survey Tissue qPCR panel 384-1
(OriGene, Cat# CSRT102), which contains 381 human tumor
tissues. Some of the samples are normal non-malignant tissue
samples, making it possible to compare expression in tumor versus
normal tissue (Table S10). Samples with irregular melt peaks were
removed, as this indicates non-specific amplification. Samples that
failed to produce any product or samples with Ct values greater than
35 were assigned a value of 40. The baseline threshold values were set
manually for each plate to ensure it was constant for the primer. Fold
change was calculated using the 2
2DDCt method relative to the mean
DCt of each gene across all the samples in the array and normalized
to the B2M gene. The expression level was therefore arbitrary but
allowed us to see in which tissues expression was high or low relative
to the mean value. Real-time PCR experiments were carried out
using the CFX96 system and SsoFast EvaGreen Supermix (Bio-Rad).
Each PCR contained 8.5 ng cDNA and 0.5 mM each primer:
KDM5A,5 9-AAGAGAAGAAGATGACGATGATGAC-39 and 59-
CCTGAAGCCTGGTGTCTGG-39; KDM5B,5 9-AAGAGTAG-
CATCAAGCAAGAACC-39 and 59-GACATACAGGTCCACAG-
CATTG-39;a n dBRD8,5 9-CATACTGTGACTGTTTCC-39 and
59-CAGCAAGGACAGCATCTTCTC-39.T h eB2M primers have
been described elsewhere [5]. The expression level of each gene in
each tissue was represented as heatmaps produced with Gitools.
Figure 6. Epigenetic landscape is defined by HDM/HMT gene expression signature. The status of HDM and HMT gene expression is
presented in red (higher expression) and green (lower expression) colors. The KDM5A, EZH2, H3K4me3 and H3K27me3 modules are shown as large
circles, either preferentially expressed (in red color) or underexpressed (in blue color). The expression of KDM5A targets and genes with H3K4me3 is
determined by the levels of HDM1 and HMT1, which are relatively high in blood cells. In leukemia cells, the level of HMT1 becomes lower, the level of
HDM2 becomes higher and as a result, the responsive H3K4me3 module is not preferentially expressed anymore. Some of the H3K4 and H3K27
trimethylated regions overlap as bivalent marks and remain poised for expression (shown as a grey area in the overlap).
doi:10.1371/journal.pone.0024023.g006
Co-Regulation of Histone-Modifying Enzymes
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e24023Supporting Information
Figure S1 Expression levels of KDM5A and KDM5B in
human tumors (TissueScan Array). Gene expression data
are presented as in Figure 5, but with sample annotation. Samples
are arranged according to tumor grade.
(TIF)
Figure S2 Expression levels of KDM5A and BRD8 in
human tumors (TissueScan Array). Gene expression data
are presented as in Figure 5, with sample annotation. Samples are
arranged according to tumor grade.
(TIF)
Table S1 Human histone demethylases and histone
methyltransferases.
(DOC)
Table S2 Absolute (log2) expression values of HDMs
and HMTs in normal human tissues (GeneAtlas). Datasets
used in Figure 2(A) are highlighted with the corresponding colors.
(XLS)
Table S3 Z-score enrichment analysis statistics for
expression of target genes of KDM5A, EZH2 and genes
displaying H3K4me3 or H3K27me3 in normal human
tissues (GeneAtlas).
(XLS)
Table S4 Correlation coefficient of expression values of
KDM5A, EZH2, KDM5A and EZH2 target genes, and
genomic regions displaying H3K4me3 and H3K27me3 in
normal human tissues (GeneAtlas).
(XLS)
Table S5 Correlation coefficient of expression values of
KDM5A and H3K4 HMTs in normal human tissues
(GeneAtlas).
(XLS)
Table S6 Normalized gene expression values (log2)o f
HDM and HMT in human cancer cell lines (GSK
database).
(XLS)
Table S7 Z-score enrichment analysis statistics for
KDM5A, EZH2 and their target gene expression in
human cancer cell lines (GSK database).
(XLS)
Table S8 Correlation coefficient of expression values of
KDM5A, EZH2, KDM5A and EZH2 target genes, and
genomic regions displaying H3K4me3 and H3K27me3 in
human cancer cell lines (GSK database).
(XLS)
Table S9 Correlation coefficient of HDM and HMT
expression values in human cancer cell lines (GSK
database).
(XLS)
Table S10 RT-qPCR data for KDM5A, KDM5B and
BRD8 (TissueScan Array). Expression values were calculated
using the 2
–DDCt method relative to the reference gene B2M.
Sample annotation was provided by OriGene.
(XLS)
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